Published in Medical Imaging Law Weekly, April 18th, 2006
The AIM dysplasia trial will compare the effectiveness of the HALO360 System against the current standard of care for Barrett esophagus, which includes regular endoscopic biopsy surveillance and appropriate medical management of associated acid reflux disease (also called GERD). Barrett esophagus, often caused by chronic GERD, is a pre-cancerous change to the lining of the esophagus that affects approximately three million U.S. adults.
Barrett sufferers are at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.